Skip to main content
Premium Trial:

Request an Annual Quote

Pressure Bio Gets $1.2M from Exercise of Warrants

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pressure BioSciences today said that it has raised $1.2 million from the exercise of preferred stock purchase warrants.

The firm said that 98,372 15-month preferred stock purchase warrants were exercised, representing 100 percent of all outstanding and unexercised 15-month warrants that could be exercised after the March 30, 2010 warrant call.

On March 30, Pressure Bio exercised its right to call all outstanding and unexercised 15-month warrants to purchase shares of the company's Series A convertible preferred stock. Each 15-month warrant was exercisable for preferred stock at an exercise price of $12.50 per share.

Pressure Bio said that the proceeds of $1.2 million were in addition to the $241,625 the firm had previously received from the voluntary exercise of 15-month warrants between November 2009 and March 30, 2010.

In Wednesday afternoon trade on the Nasdaq, shares of Pressure Bio were up 4 percent at $1.82.

The Scan

Cell Atlas of Human Lung Development Gives View of Developing Airway

Researchers have generated a cell atlas of human lung development, which they report in Cell.

Study Finds Costs of Genome Sequencing May Limit Utility in Routine Care

Researchers report in the European Journal of Human Genetics that genome sequencing for rare disease diagnoses currently has similar benefits as less expensive exome analysis.

Study Suggests Nursing Mother's Diet Can Impact Offspring's Gut Microbiome

A new Cell Host and Microbe paper finds that mice whose mothers were fed a low-fiber diet during nursing experience lasting microbiota dysbiosis and increased obesity.

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.